Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacology Study of Aerosolized Liposomal Rubitecan in NSCLC
NCT00250120Phase 2Withdrawn
- Sponsor
- The University of New Mexico
- Start
- Apr 2003
- Primary completion
- Mar 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rubitecan in non-small cell lung cancer (NSCLC), sponsored by The University of New Mexico. Primary endpoint: Pathological examination of lung tissue. Planned start Apr 2003; status: withdrawn.
02
Drugs
rubitecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00250120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00250120.